Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “FLT3-Mutated Acute Myeloid Leukemia”

94 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 94 results

Not applicableNo Longer AvailableNCT03746912
What this trial is testing

Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib

Who this might be right for
Acute Myeloid Leukemia With Gene Mutations
Daiichi Sankyo
Testing effectiveness (Phase 2)Looking for participantsNCT06022003
What this trial is testing

Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia

Who this might be right for
AML, AdultRefractory AMLRelapsed Adult AML+2 more
French Innovative Leukemia Organisation 33
Testing effectiveness (Phase 2)Study completedNCT02927262
What this trial is testing

ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

Who this might be right for
Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation
Astellas Pharma Global Development, Inc. 98
Testing effectiveness (Phase 2)Study completedNCT01830361
What this trial is testing

Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML

Who this might be right for
Acute Myeloid Leukemia
Technische Universität Dresden 18
Testing effectiveness (Phase 2)WithdrawnNCT02829840
What this trial is testing

Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)

Who this might be right for
LeukemiaFLT3-Mutated Acute Myeloid LeukemiaFLT3-Mutated High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Large-scale testing (Phase 3)Not Yet RecruitingNCT07425808
What this trial is testing

FLT3-ITD Targeted Therapy in Fit AML Patients

Who this might be right for
AML (Acute Myeloid Leukemia)
European Organisation for Research and Treatment of Cancer - EORTC 230
Large-scale testing (Phase 3)Study completedNCT03379727
What this trial is testing

Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.

Who this might be right for
Acute Myeloid Leukemia
Novartis Pharmaceuticals 301
Large-scale testing (Phase 3)UnknownNCT00651261
What this trial is testing

Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Who this might be right for
Leukemia
Alliance for Clinical Trials in Oncology 717
Early research (Phase 1)Looking for participantsNCT05886049
What this trial is testing

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia With KMT2A RearrangementAcute Myeloid Leukemia With NPM1 Mutation+1 more
National Cancer Institute (NCI) 38
Testing effectiveness (Phase 2)WithdrawnNCT03760445
What this trial is testing

HDM201 Added to CT in R/R or Newly Diagnosed AML

Who this might be right for
Leukemia, Myeloid, Acute
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07726576
What this trial is testing

Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid Leukemia

Who this might be right for
Leukemia, Myeloid, Acute
University Hospital, Bordeaux 41
Early research (Phase 1)Looking for participantsNCT06366789
What this trial is testing

Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
AML With Gene Mutations
Lomond Therapeutics Holdings, Inc. 150
Testing effectiveness (Phase 2)Study completedNCT02400281
What this trial is testing

Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients

Who this might be right for
Acute Myeloid Leukemia
Arog Pharmaceuticals, Inc. 28
Large-scale testing (Phase 3)UnknownNCT04174612
What this trial is testing

AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD Mutation
Gruppo Italiano Malattie EMatologiche dell'Adulto 172
Early research (Phase 1)Looking for participantsNCT05024552
What this trial is testing

Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD Mutation
H. Lee Moffitt Cancer Center and Research Institute 22
Early research (Phase 1)Active Not RecruitingNCT05546580
What this trial is testing

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Who this might be right for
Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia Refractory
Oryzon Genomics S.A. 50
Testing effectiveness (Phase 2)Study completedNCT03836209
What this trial is testing

Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
PrECOG, LLC. 181
Testing effectiveness (Phase 2)Study completedNCT02310321
What this trial is testing

ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.

Who this might be right for
Acute Myeloid LeukemiaFLT3-mutated Acute Myeloid Leukemia
Astellas Pharma Inc 97
Large-scale testing (Phase 3)Study completedNCT03250338
What this trial is testing

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Who this might be right for
Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
Arog Pharmaceuticals, Inc. 106
Testing effectiveness (Phase 2)Ended earlyNCT01028716
What this trial is testing

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Who this might be right for
Acute Biphenotypic LeukemiaAcute Erythroid Leukemia in RemissionAcute Leukemia in Remission+27 more
Fred Hutchinson Cancer Center 46
Next Page